Evaluation of COVID-19 antibody therapies

COVID-19 抗体疗法的评估

• 批准号: 10285866
• 负责人: Connie Schmaljohn
• 金额: $ 5.41万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10285866
• 关键词: 2019-nCoV; Antibodies; Antibody Therapy; Biological Assay; COVID-19; Detection; Development; Evaluation; Goals; Hamsters; Human; In Vitro; Mesocricetus auratus; Modeling; Pathology; Patients; Plasma; Pneumonia; Techniques; Therapeutic; assay development; in vivo evaluation; neutralizing antibody; pathogen

The IRF has engaged in development of assays for detection and semi-quantification of neutralizing antibodies to SARS-CoV-2 as possible therapeutics. Advances in identification of pathogen specific antibodies and techniques for propagating and purifying them has allowed development of antibodies as potential therapeutics with reduced possibility of complications. The IRF has been working with multiple collaborators to evaluate antibody candidates as well as convalescent plasma in in-vitro neutralizing and total antibody assays and the hamster model of COVID-19.

IRF致力于开发检测和半定量SARS-CoV-2中和抗体的分析方法，作为可能的治疗方法。病原体特异性抗体的鉴定以及繁殖和纯化技术的进步使抗体成为潜在的治疗方法，减少了并发症的可能性。国际放射免疫研究所一直在与多家合作者合作，在体外中和和总抗体分析以及新冠肺炎的仓鼠模型中评估候选抗体和恢复期血浆。